CH672987A5 - - Google Patents

Download PDF

Info

Publication number
CH672987A5
CH672987A5 CH2611/87A CH261187A CH672987A5 CH 672987 A5 CH672987 A5 CH 672987A5 CH 2611/87 A CH2611/87 A CH 2611/87A CH 261187 A CH261187 A CH 261187A CH 672987 A5 CH672987 A5 CH 672987A5
Authority
CH
Switzerland
Prior art keywords
bromocriptine
disease
therapy
day
test
Prior art date
Application number
CH2611/87A
Other languages
German (de)
English (en)
Inventor
Douglas Dr Larson
Peter Hiestand
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CH672987A5 publication Critical patent/CH672987A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CH2611/87A 1986-07-14 1987-07-09 CH672987A5 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
CH672987A5 true CH672987A5 (fr) 1990-01-31

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2611/87A CH672987A5 (fr) 1986-07-14 1987-07-09

Country Status (13)

Country Link
JP (1) JPS6323817A (fr)
KR (1) KR880001292A (fr)
AU (1) AU602154B2 (fr)
CH (1) CH672987A5 (fr)
DE (1) DE3722383A1 (fr)
DK (1) DK363887A (fr)
FR (1) FR2601245A1 (fr)
GB (1) GB2192541B (fr)
IT (1) IT1224222B (fr)
NL (1) NL8701631A (fr)
PH (1) PH24525A (fr)
SE (1) SE8702843L (fr)
ZA (1) ZA875145B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (fr) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Utilisation de la dopamine et/ou d'agonistes dopaminergiques pour la préparation de médicaments pour le traitement du tractus digestif
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5716933A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
CA2030174C (fr) * 1990-01-10 1996-12-24 Anthony H. Cincotta Procede pour la reduction a long terme des reserves lipidiques, de l'insulinoresistance, de l'hyperinsulinemie et de l'hypoglycemie chez les vertebres
CZ282909B6 (cs) * 1991-12-23 1997-11-12 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Použití agonisty dopaminu a stimulátoru prolaktinu pro přípravu farmaceutického přípravku a tento farmaceutický přípravek
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
AU2007324706B2 (en) * 2006-11-23 2013-09-05 Sinoxa Pharma Gmbh Pharmaceutical compositions for the treatment of capillary arteriopathy
EP3445362B1 (fr) * 2016-04-20 2021-09-22 VeroScience LLC Composition et procédé de traitement de troubles métaboliques
WO2019079623A1 (fr) 2017-10-18 2019-04-25 Veroscience Llc Formulations de bromocriptine améliorées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.

Also Published As

Publication number Publication date
PH24525A (en) 1990-07-18
DK363887D0 (da) 1987-07-13
AU7558787A (en) 1988-01-21
GB2192541A (en) 1988-01-20
JPS6323817A (ja) 1988-02-01
FR2601245A1 (fr) 1988-01-15
GB8716323D0 (en) 1987-08-19
SE8702843D0 (sv) 1987-07-13
IT1224222B (it) 1990-09-26
NL8701631A (nl) 1988-02-01
DK363887A (da) 1988-01-15
ZA875145B (en) 1989-02-22
IT8748160A0 (it) 1987-07-10
AU602154B2 (en) 1990-10-04
KR880001292A (ko) 1988-04-22
SE8702843L (sv) 1988-01-15
GB2192541B (en) 1990-05-02
DE3722383A1 (de) 1988-01-28

Similar Documents

Publication Publication Date Title
CH672987A5 (fr)
DE3247062C2 (fr)
DE3526545A1 (de) Neue pharmazeutische anwendung von (nva)(pfeil hoch)2(pfeil hoch)- und dihydro-(val)(pfeil hoch)2(pfeil hoch)-cyclosporin
DE69925488T2 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE3590035T1 (de) Diphenhydramin enthaltende, analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung
DE69634092T2 (de) Herstellung von antikörpern
CH666188A5 (de) Immuno-regulator in form einer pharmazeutischen zusammensetzung.
WO1990014829A1 (fr) Derives de lysolecithine pour le traitement de maladies auto-immunitaires
DE3390419T1 (de) Arzneimittel zur Behandlung der Ulkuskrankheit
EP0236390B1 (fr) Agent contre la sclerose multiple
WO2002038150A1 (fr) ACTIVATEURS DE RECEPTEURS α, β ACTIVES PAR DES PROLIFERATEURS DE PEROXYSOME EN TANT QUE MEDICAMENTS POUR LE TRAITEMENT DE TROUBLES CUTANES DE SOURCE IMMUNOLOGIQUE
DE4136215A1 (de) Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
DE69630527T2 (de) Vorbeugung einer krankheit mit diabetes charakter
DE3916417C2 (fr)
DE3715218A1 (de) Arzneimittel zur stimulation des lernens und zur verbesserung des gedaechtnisses
Kennedy et al. Spinal changes in the neuropathy of thallium poisoning: a case with neuropathological studies
DE60206280T2 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
WO2003043648A2 (fr) Composition pharmaceutique contenant sfcyr iib ou sfcyr iii
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
DE1902865A1 (de) Substituierte Insulin-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen
DE60020580T2 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam-1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren, enthalten
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
DE4435525C2 (de) Präparat zur Behandlung von Entmarkungsenzephalitiden
DE19636252C2 (de) Pharmazeutisches Kombinationspräparat zur Behandlung von rheumatischen Erkrankungen
WO1991008746A1 (fr) Elimination de lymphocytes actifs

Legal Events

Date Code Title Description
PL Patent ceased